Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl-(6S)-tetrahydrofolate

US10463666B2 · kind B2 · utility

Assignees

• MERCK & CIE · CH
• Bayer Intellectual Property GmbH · DE

Inventors

• Kai Strothmann · Oberursel, DE
• Gavin Welch Wasserfall-Smith · Berlin, DE
• Klaus Pietrzik · Meckenheim, DE
• Kristina King · Berlin, DE
• Rudolf Moser · Schaffhausen, CH

Key dates

• Filing date: Dec 10, 2015
• Grant date: Nov 5, 2019
• Expiry date: Jun 28, 2036

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to a pharmaceutical composition which comprises progestogens, preferably drospirenone, estrogens, preferably ethinylestradiol and 5-methyl-(6S)-tetrahydrofolate, can be employed as oral contraceptive and moreover prevents disorders caused by folate deficiency in the consumers, in particular cardiovascular disorders and, after conception of the embryo, congenital malformations caused by folate deficiency such as, for example, neural tube defects, ventricular valve defects, urogenital defects, and cleft lip, jaw and palate, without masking the symptoms of vitamin B12 deficiency, and at the same time even in the case of homozygous or heterozygous polymorphism of methylenetetrahydrofolate reductase facilitates unimpaired utilizability of the folate component 5-methyl-(6S)-tetrahydrofolate by the body and thus its biological activity for preventing the abovementioned congenital malformations caused by folate deficiency. In addition, a prolonged protective effect is maintained after discontinuation of the contraceptive.